| VON HIPPEL-LIN DAU (VHL) SYNDROME
Thus, this partial inhibition of HIF downstream genes may limit the efficacy of TKI for RCC treatment. 6 In this notion, HIF2a antagonist has been developed and its efficacy is under investigation. 7 2 | BIRT-HOGG-DUB E' (BHD ) SYNDROME 9 | BAP1 CANCER SUSCEPTIBILITY SYNDR OME
| TUBEROUS SCLEROSIS (TSC)
One of the biggest findings in whole-exome sequencing for sporadic kidney cancer using next-generation sequencing technology are the recurrent alterations in chromatin remodeling genes in clear cell and papillary RCC. Among these alterations, BAP1 mutations were found in 15% of sporadic RCC. 4,5 BAP1 mutation is a critical driver for renal tumorigenesis as double inactivation of murine Vhl and Bap1 develops malignant lesions in mouse kidney. 50 Interestingly, a later study on hereditary kidney cancer reported that a germline BAP1 mutation was found in kidney cancer kindred. 51 BAP1 is a tumor suppressor for multiple organs and germline BAP1 mutation drives malignant mesothelioma and malignant melanoma in uvea and skin.
BAP1 deubiquitinates histone H2A at K119 and chromatin immunoprecipitation and DNA sequencing (ChIP-seq) for BAP1 protein showed that significant BAP1 peaks locate near the transcription start sites of 5731 genes which may include the targets for BAP1-deficient kidney cancer. 
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